Skip to Content
Merck

A1276

Amastatin hydrochloride hydrate

powder, ≥97% (HPLC)

Synonym(s):

(2S,3R)-3-Amino-2-hydroxy-5-methylhexanoyl-Val-Val-Asp hydrochloride hydrate

Sign In to View Organizational & Contract Pricing.

Select a Size

0.5 MG

CHF 167.00

1 MG

CHF 266.00

5 MG

CHF 952.00

10 MG

CHF 1’540.00

25 MG

CHF 3’200.00

CHF 167.00


Check Cart for Availability


About This Item

Empirical Formula (Hill Notation):
C21H38N4O8 · HCl · xH2O
CAS Number:
Molecular Weight:
511.01 (anhydrous basis)
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352202
MDL number:
Beilstein/REAXYS Number:
8888370

Skip To

Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Amastatin hydrochloride hydrate, ≥97% (HPLC)

InChI

1S/C21H38N4O8.ClH.H2O/c1-9(2)7-12(22)17(28)20(31)25-16(11(5)6)19(30)24-15(10(3)4)18(29)23-13(21(32)33)8-14(26)27;;/h9-13,15-17,28H,7-8,22H2,1-6H3,(H,23,29)(H,24,30)(H,25,31)(H,26,27)(H,32,33);1H;1H2/t12-,13+,15+,16+,17+;;/m1../s1

SMILES string

Cl[H].[H]O[H].CC(C)C[C@@H](N)[C@H](O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O

InChI key

WBYDQJQQTMJMQH-AFROIDPFSA-N

biological source

synthetic (organic)

assay

≥97% (HPLC)

form

powder

mp

202-205 °C

solubility

methanol: 1 mM (Stock solution stable for 1 month at −20 °C. Working solution stable for 1 day.)

antibiotic activity spectrum

neoplastics

mode of action

enzyme | inhibits

storage temp.

−20°C

Quality Level

Looking for similar products? Visit Product Comparison Guide

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item
A6191SML0056B8385
biological source

synthetic (organic)

biological source

Streptomyces sp.

biological source

-

biological source

synthetic (organic)

assay

≥97% (HPLC)

assay

-

assay

≥98% (HPLC)

assay

≥98% (HPLC)

Quality Level

200

Quality Level

300

Quality Level

100

Quality Level

300

form

powder

form

lyophilized powder

form

powder

form

powder

solubility

methanol: 1 mM (Stock solution stable for 1 month at −20 °C. Working solution stable for 1 day.)

solubility

H2O: 50 mg/mL, 1-butanol: soluble, 1-propanol: soluble, DMSO: soluble, ethanol: soluble, methanol: soluble

solubility

H2O: ≥22 M

solubility

water: 25 mg/mL, clear to very slightly hazy, colorless

storage temp.

−20°C

storage temp.

−20°C

storage temp.

2-8°C

storage temp.

−20°C

Biochem/physiol Actions

Amastatin is a slow, tight-binding inhibitor of aminopeptidases. It inhibits cytosolic leucine aminopeptidase (EC.3.4.11.1), microsomal aminopeptidase M (EC.3.4.11.2) and bacterial leucine aminopeptidase (EC.3.4.11.10). It is less effective against aminopeptidase A (EC 3.4.11.7), the enzyme that converts Angiotensin II to Angiotensin III. Effective concentration: 1-10 μM.
It inhibits cytosolic leucine aminopeptidase (EC.3.4.11.1), microsomal aminopeptidase M (EC.3.4.11.2) and bacterial leucine aminopeptidase (EC.3.4.11.10). It is less effective against aminopeptidase A (EC 3.4.11.7), the enzyme that converts angiotensin II to angiotensin III. Potentiates the CNS effects of vasopressin and oxytocin in vivo.

Effective concentration: 1-10 μM.

General description

Chemical structure: peptide

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Zollner, H.
Handbook of Enzyme Inhibitors, 2nd Ed., 547-547 (1993)
Beynon, R.J. and Bond, J.S.
Proteolytic Enzymes: A Practical Approach, 247-247 (1989)
Yu Wang et al.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 35(3), e21419-e21419 (2021-02-11)
In the early phase of the Coronavirus disease 2019 (COVID-19) pandemic, it was postulated that the renin-angiotensin-system inhibitors (RASi) increase the infection risk. This was primarily based on numerous reports, which stated that the RASi could increase the organ Angiotensin-converting

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service